Kidney Transplant Donor Selection: Blood Group and HLA-Incompatible Transplants

This is antibody-mediated rejection (AMR), one of two categories of acute rejection alongside cell-mediated rejection (ACR), and a kidney biopsy is needed to tell them apart. Treatment usually starts with methylprednisolone pulses, escalating to anti-thymocyte globulin or plasmapheresis if that isn't enough. In over a decade, hyperacute rejection has not been seen in blood-compatible transplants at this centre, and most rejection today is reversible when caught and treated promptly, the real danger comes from delayed treatment, not from the rejection episode itself.

Donation has to come from love and compassion, never pressure. What actually works is reframing donation as a chance for the donor to become healthier: the thorough medical workup required for donor clearance means any underlying problem gets caught and treated, so donors go on to outlive their peer group rather than being harmed by donating. Where genuine pressure would otherwise be needed, keeping the recipient on dialysis while continuing to look for a willing donor is the ethical path, alongside broader deceased-donor campaigns to reduce reliance on living donors altogether.

It is being tried, but the outlook is not promising because of tissue rejection and the risk of transmitting animal viruses, including parvovirus, into the recipient, so the success of xenotransplantation is still genuinely questionable. Far more promising is tissue-engineered, artificially grown organs: a related technique already in use is tissue-engineered buccal mucosa grafting for urethral stricture, where a small piece of cheek tissue is cultured in a lab and implanted into the urethra, a real, working example of the technology-biology merger that is likely to define the field's near future.

A routine mini-incision laparoscopic transplant package costs approximately USD 13,000-14,000, with an additional USD 3,000 for a fully robotic transplant. Donor selection starts with a related donor within the immediate family, confirmed by DNA testing, with extended family only considered if no closer relative is eligible, alongside blood-group and basic health workup. Transplant is generally advised once creatinine exceeds 7, with signs of fluid overload or hyperkalaemia, shrunken kidneys with reduced urine output, and a raised PTH indicating the kidneys will not recover, with an practical age ceiling of around 80 depending on the patient's actual physiological fitness.

These patients do fairly well. CD4 count is checked and optimised before travel, with good medical management started well ahead of transplant so patients only travel once they fall into a suitable category. The immediate transplant risk in HIV-positive patients is similar to other patients, though later opportunistic-infection-related complications run somewhat higher, so immunosuppression is adjusted accordingly, for example avoiding routine ATG in favour of a gentler induction agent so immunity is not suppressed as heavily.

Yes. It is the second choice after a compatible donor, and is managed based on the recipient's antibody titre against the donor's blood group: titres up to 1:64 respond to plasmapheresis, higher titres need immunoadsorption column filtration, and transplant proceeds once titres fall below 1:8, alongside a rituximab-based protocol.

No. The determining test is the cross match, not the HLA match itself. A negative CDC and flow cross match clears the transplant; if flow is positive, donor-specific antibody testing quantifies the actual risk and guides whether plasmapheresis is needed first.